|Other Names||Squalene synthase, SQS, SS, FPP:FPP farnesyltransferase, Farnesyl-diphosphate farnesyltransferase, FDFT1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2417a was selected from the N-term region of human FDFT1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Endoplasmic reticulum membrane; Multi-pass membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
FDFT1 catalyzes the first step in the cholesterol biosynthetic pathway, the conversion of trans-farnesyldiphosphate to squalene. The loss of promoter activity and response to sterols for FDFT1 is localized to a 69-bp section positioned 131 bp 5-prime to the transcription start site. Sequence analysis of this region shows that it contains a sterol regulatory element-1 (SRE1) previously identified in other sterol regulated genes and 2 putative NF1 binding sites.
Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002).Soltis, D.A., et al., Arch. Biochem. Biophys. 316(2):713-723 (1995).Jiang, G., et al., J. Biol. Chem. 268(17):12818-12824 (1993).Robinson, G.W., et al., Mol. Cell. Biol. 13(5):2706-2717 (1993).Summers, C., et al., Gene 136 (1-2Che), 185-192 (1993).
If you have any additional inquiries please email technical services at email@example.com.